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Abstract
Cognitive impairment and dementia are the most frequently occurring non-
motor symptoms in Parkinson’s disease (PD), yet these symptoms are mostly 
overlooked and are not diagnosed and treated exceptionally like the cardinal 
motor symptoms in clinical practice. It is only in the late twentieth century that 
dementia has been recognized as a major clinical manifestation in PD. The possible 
mechanisms that cause dementia are complex with different patterns of cognitive 
behavior that disrupt the patient’s quality of life. It is preeminently considered that 
the cholinergic denervation in the basal forebrain region mediates dementia in PD. 
So far, dopamine-based therapy is the key objective in the treatment of PD and the 
nonmotor symptoms are mostly neglected. Interestingly, the loss of Tyrosine kinase 
receptor-A (TrkA) signaling in basal forebrain results in neuronal atrophy, which 
precedes cholinergic denervation and cognitive impairment. Nerve Growth Factor 
(NGF) binds to TrkA receptors, inducing a cascade of events like PI-3Kinase/Akt 
and MAPK signaling pathways that render cholinergic degeneration and upregulate 
the choline acetyltransferase activity and neuronal differentiation. Hence, TrkA 
receptor activation by small molecules might attenuate the dementia symptoms 
associated with PD, and may be targeted as a novel treatment strategy along with 
regular clinical agents.
Keywords: dementia, Trk receptors, nonmotor symptoms, cholinergic 
neurotransmission, neuroprotective signaling pathways
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with a wide 
range of clinical symptoms. Even though PD is traditionally considered a disorder 
of movement, mounting number of evidences emerged that concerned the con-
nection of dementia and other nonmotor symptoms (NMS) that occurs from the 
early stages of PD and contradicted the statement of James Parkinson’s (1817) “the 
senses and intellects being uninjured” [1, 2]. But more attention was paid to dementia 
and cognitive impairment associated with PD only from the levodopa era and most 
researchers agreed that dementia (particularly organic dementia) occurs more 
frequently in patients suffering from PD [1, 3].
Jeffery Cummings reported a mean dementia prevalence of 40% in his review 
of 27 studies that included 4336 patients with PD [4]. In spite of these studies 
being crucially considered, most studies represented patients with unselected 
PD population based on patients being referred to neurology clinics and some 
studies did not specify the exclusion of patients who were already diagnosed with 
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Dementia with Lewy Bodies (DLB) [4, 5]. Another systematic review of 13 studies 
employing strict methodological inclusion and exclusions screened 1767 patients, 
out of which 554 were diagnosed with dementia, reflecting a prevalence of 31.3%. 
This review also proclaimed the prevalence of dementia in general population that 
included PD patients, and revealed that 3–4% of dementia in patients was due to 
dementia associated with PD, which sums to a total of 0.3–0.5% among the overall 
general population aged 65 years and above [5, 6]. Most of the studies evaluating 
the incidence of dementia associated with PD are based on longitudinal study of 
community-based cohorts, from which the prevalence of PD has been estimated 
[5]. Some studies revealed incident rates of 95 [7] and 112 [8] in 1000 patient years, 
revealing that approximately 10% of the patients diagnosed with PD are at a higher 
risk category and develop dementia within 10 years [5, 7, 8]. In 2008, Hely and team 
reported the data from their 20-year follow-up multi-center longitudinal study, 
which demonstrated that up to 80% of patients with PD will develop dementia over 
a 20-year period and this finding implies that most patients with PD will eventually 
develop dementia if they live long enough [9].
Dementia currently is considered the most significant nonmotor symptom 
(NMS) in PD due to its crucial contribution towards the morbidity and mortality of 
the disease and has also evinced remarkable clinical consequences to the patients in 
terms of disability, increased risk of psychosis, and reduced Quality of Life (QoL) 
[5]. Recent advancements in treatment have increased patient survival, which 
has in turn increased the incidence and prevalence of dementia in PD population. 
Although a slight cognitive deficit is sometimes noticed in the initial stages of PD, 
overt dementia and cognitive impairment manifest more commonly in the later 
stages when the patient’s age advances [2]. The prevalence of dementia and cogni-
tive impairment remains controversial and eminently depends upon the study 
population and on the diagnostic tools and methods used. Various studies estimat-
ing the frequency of dementia and cognitive impairment in PD have used a variety 
of methods and study designs that may alter study outcomes [2, 5].
The cholinergic neurons are projected in three major areas in the brain: brain-
stem [10], striatum [11], and the basal forebrain (BF) region [12]. The cholinergic 
projection in the brainstem extends to the thalamus and it functions in risk aversion 
[11, 13, 14], while the cholinergic interneurons in the striatum play a key role in the 
regulation of dopamine secretion [11]. The basal forebrain cholinergic neurotrans-
mission system principally originates in the medial septum, vertical limb of the 
diagonal band (MS/VDB), and the nucleus basalis, which extends to the olfactory 
bulb, neocortex hippocampus, and amygdala [12, 15]. Basal forebrain cholinergic 
neurons, especially the ones in the nucleus basalis, are reported to selectively 
degenerate in certain neurodegenerative disorders and have long been a key focus 
of research in the determination of the relation between acetylcholine (ACh) and 
memory [16].
It is widely accepted that the cholinergic neurotransmission system in the basal 
forebrain region is for normal cognitive function, especially memory and attention. 
Degeneration of the cholinergic neurotransmission is thought to be responsible for 
cognitive impairment and dementia associated with neurodegenerative disorders 
like PD and Alzheimer’s disease (AD) [17–19]. Many studies have reported that 
deficits in cholinergic neurotransmission and signaling are often coupled with 
neurodegenerative and attentional disorders and impaired cognitive control [20]. 
While the possible mechanisms resulting in such manifestations are complex and 
heterogenous and lead to different patterns of cognition and behavior that majorly 
affects the patient’s QoL. The preeminent mechanism through which cholinergic 
signaling influences cognition is predicted to be direct cholinergic stimulation of 
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pre- and post-synaptic neuronal receptors. Neuroinflammation is considered to 
be the hallmark pathology in neurodegenerative disorders like Parkinson’s and 
Alzheimer’s and may also contribute to other neurodegenerative disorders [10, 21].
Neurotrophins are proteins that are identified as survival factors of sensory and 
sympathetic neurons and have been shown to have an imperative control of sur-
vival, development, and functioning of neurons in both the peripheral and central 
nervous system [22]. The neurotrophin family is comprised of nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and 
neurotrophin-4 (NT-4). Pro-neurotrophins bind to and signal via two principal 
receptor types: p75NTR and TRK receptors. There are three TRK receptors: TRKA, 
TRKB, and TRKC, and each receptor selectively binds to different neurotrophins: 
NGF binds to TRKA; BDNF and NT4 bind to TRKB; and NT3 binds to TRKC 
[23, 24]. TRKB and TRKC are widely found in neuronal populations throughout 
the central and peripheral nervous system in humans, while the distribution of 
TRKA is mostly restricted to the basal forebrain cholinergic region, the dorsal root 
ganglion, and sympathetic neurons [25]. Cholinergic neurons that do not transport 
NGF are severely shrunken and downregulate the expression of TRKA receptor 
[26]. Neurotrophins are thought to be a promising therapy for various neurodegen-
erative disorders including PD and AD. Because of their poor bioavailability and 
pharmacokinetic properties, make poor drug entities [27]. The major drawback in 
neurotrophin therapy is reduced passage of peptide hormones across the blood–
brain barrier (BBB); peripheral administration of peptide hormones resulted in a 
slight increase in the intracranial neurotrophin concentration. Hence, consider-
able efforts are devoted towards the discovery of appropriate small molecule 
neurotrophin peptidomimetics that can mimic the binding of selective peptides 
and elicit neuronal regenerative responses like that of neurotrophins [28]. Hence, 
this chapter points out the risk factors, progression, and possible novel targets for 
Parkinson’s dementia.
2. Risk factors of dementia in PD
Many demographic features, along with cardinal motor and NMS, have been 
identified as potential risk factors and predictors of dementia in PD [5, 29]. A 
study outlined that the patient’s age was reported to be a common risk factor for 
dementia in a PD population [30] and some studies also suggested that advanced 
disease stage, specific subtypes of PD (e.g., akinetic-subtype), and certain NMS 
like olfactory dysfunction, mild cognitive impairment and mood disorders, rapid 
eye movement sleep behavior disorder (RBD), and hallucinations are reported to be 
strong predictors of dementia in PD [29].
2.1 Age
A number of studies have proposed that the patient’s age and the age of onset of 
PD are both associated with a higher risk of dementia, and interestingly, patient’s 
age along with increasing severity of the cardinal motor symptoms and duration 
of the disease are considered to be the key risk factors of dementia in PD [30, 31]. 
Based on such proposals, Levy concluded that aging may still play a substantive 
role in the pathogenesis and progression of the disease and the pathogenic cascades 
should further account not only for the relative selectivity of the disease process to 
the substantia nigra pars compacta but also for the widespread involvement of the 
cholinergic structures in late clinical stages of the disease [32].
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2.2 Olfactory dysfunction
Olfactory dysfunction, or hyposmia, is frequently observed in the pre-motor 
(pre symptomatic stage) phase of the disease, even before dopaminergic denerva-
tion is evident and most of the evidence highlights the involvement of cholinergic 
dysfunction in hyposmia and several other aspects of olfaction [33]. The preva-
lence of hyposmia in PD patients is reported to be very high with up to 95% being 
affected [34]. A study conducted in 2012 including PD patients with hyposmia 
(prevalence ∼55%) reported that in contrast to PD patients without hyposmia, PD 
patients with hyposmia exhibited mild impairment in general cognition, memory, 
and visuoperceptual functioning. After a follow-up period of 3 years, it was found 
that the cognitive impairment in the patients with hyposmia was more severe and 
their scores on Mini-Mental State Examination became significantly worse than 
compared with that of patients without hyposmia [35].
2.3 Cognition and mood disturbances
Cognitive impairment and dementia are frequent findings in PD patients. 
Approximately 75% of the PD patients who survive for more than 10 years are 
expected to develop dementia [36]. Neuropathological studies have shown that 
cognitive impairment in PD is associated with the cholinergic loss in BF. Reductions 
of acetylcholine esterase (AChE) activity in frontal cortex are found to be greater 
in Parkinson’s disease dementia (PDD) compared to PD without dementia [37]. 
Major depression and apathy are commonly reported in PD; although alterations in 
the monoaminergic systems is thought to result in mood changes, there is evidence 
that the severity of cortical cholinergic degeneration is strongly associated with 
the presence of depression and apathy in PD [38]. Depression in PD appears to 
be associated with cognitive deficits, suggesting a common mechanism, and this 
hypothesis is justified by the observation that depression is one of the major risk 
factor for dementia in PD [39, 40].
2.4 Random eye movement sleep behavior disorder (RBD)
RBD is a commonly reported NMS in PD and is mostly reported to precede 
cognitive impairment and dementia associated with PD [41, 42]. RBD is mainly 
characterized by disturbed atonia during random eye movement sleep, which 
results in abnormal motor manifestations [42, 43]. The principal mechanism 
underlying RBD is considered to be cholinergic dysfunction, which is also assumed 
to play an imperative role between RBD and increased dementia in PD patients 
[42–44]. A brain imaging study exposed that cholinergic denervation was strongly 
associated with RBD, and 33.8% of 80 patients presented with RBD. The patients 
underwent acetylcholine esterase and dopaminergic dual-tracer PET scanning. The 
scan reports revealed that patients who presented with RBD and related symptoms 
exhibited decreased cortical, neocortical, and thalamic cholinergic innervations 
when compared to PD patients without RBD and related symptoms. This study also 
summarized that cholinergic denervation can occur in early stages of the disease 
[43–45].
2.5 Visual hallucinations
Visual hallucinations are generally considered as the main neuropsychiatric fea-
ture [46] and it is commonly observed in patients with PD [46, 47], particularly in 
patients with dementia [48]. A longitudinal study found that visual hallucinations 
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are associated with higher risk of developing dementia [49]. The relationship 
between hallucinations and dementia is thought to be related to both Lewy body 
pathology [50] and cholinergic disturbance [51].
3. Pathophysiology of dementia in PD
The mechanism behind dementia in PD remains uncertain, and a number 
of neurochemical and neuropathological changes are assumed to be involved. 
Dementia in PD is thought to be a result of several cortical and subcortical changes, 
mainly involving the cortical cholinergic deficiency due to neurodegeneration in the 
nucleus basalis of Meynert (nbM) and the subcortical pathology, including dopa-
minergic deficiency in the caudate and in mesocortical areas [52]. It is also reported 
that additional AD-like pathology and the presence of Lewy bodies are likely to 
furthermore complicate cognitive impairment and dementia [53]. Cognitive impair-
ment in non-demented PD patients is thought to be caused by the depletion of the 
dopaminergic system in the frontal cortex, which results from degeneration of the 
mesocortical dopaminergic system mainly projecting from the ventral tegmental 
area (VTA) [54].
It has also been reported that the loss of neurons in the locus coeruleus along 
with noradrenergic deficiency in the cortex region may result in dementia in PD. 
However, this neuropathology was not found or reported in other similar stud-
ies. The loss of serotonergic neurons in the dorsal raphe nucleus (DRN) is mainly 
reported to be associated with depression among PD patients and comparisons 
between demented and non-demented PD patients did not find differences in 
neuronal counts in the DRN [55].
In an attempt to establish a connection between dementia in PD and dimin-
ished monoaminergic activity in their study, instead identified the association 
between cholinergic deficiency and dementia and reported that cholinergic 
deficit is implicated in the neuropathology of dementia in PD and in DLB  
[52, 56]. It was also reported that more profound and definite cholinergic deple-
tion was found in the nbM region in PD brains when compared to that of AD 
brains [57]. This hypothesis was further supported by the fact that anti-choliner-
gics elicited cognitive impairment in PD patients and by the therapeutic benefits 
of acetylcholine esterase inhibitors in the management of symptoms associated 
with dementia [58]. Adjacent to these neuropathological changes, important 
AD-like cortical changes have also been reported and implicated especially due 
to the abundant expression of AD-neurites in PD patients with dementia, which 
also correlates with the severity of dementia in PD [58, 59]. Basal forebrain (BF) 
cholinergic neurons within the nucleus basalis are the major source of choliner-
gic innervation to the cerebral cortex and play a key role in cognition and atten-
tion. In conditions like PD and AD, these cortical projection neurons undergo 
extensive degeneration, which correlates with clinical severity and disease 
duration. BF cholinergic neurons require Nerve Growth Factor (NGF) for their 
survival and biologic activity [60]. NGF mediates its actions on the BF cholin-
ergic neurons via binding to the low-specificity, low-affinity p75NTR and the 
NGF-specific high-affinity TrkA receptor. Both the receptors are expressed and 
localized at cholinergic cell bodies and at nerve terminals [61]. The embryonic 
development of the BF cholinergic neurons is highly dependent on the expres-
sion of NGF and TrkA expression. Aging causes mammalian NGF expression and 
release to diminish to basal levels; however, the trophic dependence of choliner-
gic neurons on NGF remains critical even in the mature and fully differentiated 
CNS [61, 62].
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Figure 1. 
Neurotrophin-TRK receptors signaling pathway. Neurotrophins binds and activates the TRK receptors, which 
phosphorylates the SCH domain that in turn triggers the RAS mediated MAPK signaling pathway and PI3-K/
AKT pro-survival pathway that results in neuronal differentiation and survival.
4. TrkA receptor activation, a new target in Parkinson’s dementia
Neurotrophins are proteins that were initially identified as survival factors of 
sensory and sympathetic neurons, and since have been shown to have an impera-
tive control of survival, development, and functioning of neurons in both the 
peripheral and central nervous system [22]. The neurotrophin family comprises 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neuro-
trophin-3 (NT-3), and neurotrophin-4 (NT-4). These neurotrophins are formerly 
synthesized in the endoplasmic reticulum as pre-proproteins, and cleavage of 
the signal peptide of pre-proproteins converts these into pro-neurotrophins. 
In the trans-Golgi network and in secretory vesicles, pro-neurotrophins dimer-
ize and are proteolytically processed by proprotein convertase subtilisin kexin 
(PCSK) enzymes to their mature forms prior to their release from the cell. Pro-
neurotrophins binds to and signals via two principal receptors: p75NTR and the TRK 
receptors. p75NTR, a tumor necrosis factor (TNF) receptor family member that 
unselectively binds all of the neurotrophins and lacks known intrinsic enzymatic 
activity but recruits signaling adaptors and modulates molecular signaling via 
TRK receptors [25]. Depending on the expression of TRK receptors and other 
intercellular signaling adaptors, p75NTR induced effects vary a wide range including 
neuronal cell survival, regulation, proliferation, and inhibition of neurite growth 
and is also known to regulate various proteins and pathways like phosphoinositide 
3-kinase (PI3K)–AKT pathway, nuclear factor-κB, (NF-κB), and mitogen-activated 
protein kinase (MAPK) [63–65].
There are three TRK receptors: TRKA, TRKB, and TRKC, and each neurotrophin 
selectively binds to different receptors: NGF binds to TRKA; BDNF and NT4 bind to 
TRKB; and NT3 binds to TRKC [23, 24]. In addition, there is heterologous binding, 
with NT3 and NT4 both provoking some activation of TRKA, and NT3 prompting 
some activation of TRKB [23, 25]. TRKB and TRKC are widely found in neuronal 
populations throughout the central and peripheral nervous system in humans, while 
the distribution of TRKA is mostly restricted to basal forebrain cholinergic region, 
the dorsal root ganglion, and in sympathetic neurons [25]. TRK signaling occurs 
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principally through three tyrosine kinase–mediated pathways: MAPK–ERK (extra-
cellular signal-regulated kinase) pathway, PI3K–AKT pathway, and phospholipase 
Cγ-1 (PLCγ-1)–PKC pathway (summarized in Figure 1). The effects elicited via 
these signaling pathways predominantly endorse cell survival and differentiation 
[24]. Even though these neurotrophin receptors possess overlapping expression pat-
terns and functions, certain neural mechanisms, such as NGF-TRKA mediated basal 
forebrain cholinergic upregulation [66], BDNF–TRKB mediated improved synaptic 
plasticity, and NT3-TRKC mediated survival of peripheral proprioceptive neurons, 
are receptor specific. The receptor-ligand specificity is mentioned in Table 1.
4.1 TrkA neuroprotective signaling pathways
NGF was discovered as a molecule that promoted survival and differentia-
tion of sensory and sympathetic neurons. Cellular responses to NGF are elicited 
through binding and activation of TRKA receptor [67]. Major pathways activated 
include Ras stimulated MAPK/ERK protein kinase pathway, PI3-K stimulation 
of AKT, and PLCγ1-dependent generation of IP3 and diacylglycerol (DAG) that 
results in mobilization of calcium stores and activation of Ca2+ and DAG-regulated 
protein kinases [22]. These signaling pathways prevent apoptotic cell death and 
promote cellular differentiation, axon regulation, and choline acetyl transferase 
(ChAT) upregulation [68]. NGF mediated neuroprotective signaling most likely 
depends on PI3K/Akt in PC12 cells, cerebellar cortex, sympathetic, sensory and 
motor neurons [69]. The neuroprotective pathways induced by TrkA receptor is 
summarized in Figure 1.
4.1.1 RAS signaling pathway
Reticular Activating System (RAS) regulates neuronal differentiation and also 
promotes neuronal survival, through either the PI3K or the mitogen-activated protein 
kinase (MAPK)/Extracellular-Signal-Regulated Kinase (ERK) pathways. In PC12 
cells, different adaptors appear to facilitate transient versus prolonged activation of 
ERK signaling. In each case, phosphorylation of Y490 initiates the recruitment of an 
adaptor protein, initiating a cascade of signaling events [69]. Shc recruitment and 
phosphorylation in turn results in recruitment to the membrane complex of the adap-
tor Grb-2 and the Ras exchange factor son of Sevenless (SOS), thereby stimulating 
transient activation of Ras. Ras in turn activates PI3K, p38 MAPK/MAPK-activating 
protein kinase 2 pathway, and the c-Raf/ERK pathway [70].
4.1.2 PI3K signaling pathway
Trk receptors can activate PI3K at least via two distinct pathways, depending 
upon the neuronal subpopulations. In many neurons, Ras-dependent activation 
of PI3K is the most important pathway through which neurotrophins promote cell 
Receptors Preferred ligand Non-preferred ligand Non-ligand
TRKA NGF NT3, NT4 BDNF
TRKB BDNF NT3 NGF
TRKC NT3 None NGF, BDNF AND NT4
P75NTR NGF, BDNF, NT3, AND NT4 None None
Table 1. 
Binding specificity of neurotrophins.
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survival. In some cells, however, PI3K is also activated by three adaptor proteins, 
Shc, Grb-2, and Gab-1 [71]. Shc binding with phosphorylated Y490 results in 
recruitment of Grb-2. Phosphorylated Grb-2 provides a docking site for Gab-1, 
which is bound by PI3K [72]. In some neurons, the insulin receptor substrate 
(IRS)-1 is also phosphorylated by neurotrophins that recruit and activate the PI3K 
signaling pathway [73]. In addition to providing a linker for activation of PI3K, 
Gab-1 also nucleates formation of a complex including the protein phosphatase 
Shp-2, [74] which enhances activation of the Ras/ERK signaling pathway [72, 75].
4.1.3 PLC-γ1 signaling pathway
Phosphorylated Y785 on TrkA and similarly placed residues on other Trk recep-
tors recruit the PLC-γ1 signaling pathway. The Trk kinase then phosphorylates 
and activates PLC-γ1, which acts to hydrolyze phosphatidylinositides to generate 
diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP3). IP3 induces the release 
of calcium ion (Ca2+) stores, thereby increasing the levels of cytoplasmic Ca2+, 
which in turn activates many pathways controlled by Ca2+. It has been shown that 
NGF activates DAG-regulated protein kinase and protein kinase C (PKC)-δ, which 
is required for ERK cascade activation and neurite outgrowth [76]. PKC-δ appears 
to act between Raf and MAPK/ERK in this signaling cascade.
5. TrkA activation and cholinergic regeneration
TrkA gene expression is under positive feedback from NGF signaling, and this 
pathway may be disturbed by reduced retrograde transport of cortical NGF to nbM 
cholinergic consumer neurons [77]. In sustenance of this hypothesis, NGF levels are 
stable [78] or increased [79] in the cortex, whereas the levels of NGF are decreased 
in nbM [77]. Notably, defective retrograde transport of NGF within cholinergic 
projection neurons was reported in a transgenic mouse model of Down syndrome 
[80]. In aged rats, these neurons exhibited a pronounced reduction in NGF ret-
rograde transport, TrkA protein expression, and severe atrophy. Defective NGF 
retrograde transport may therefore underlie the reductions in nbM TrkA gene and 
protein expression observed in single nbM neurons, leading to eventual reduction 
of TrkA protein in cortical projection sites [81] and further trepidations in NGF 
signaling within the nbM. This putative “off trk” cycle of deficient NGF signal-
ing may contribute to the selective degeneration of cholinergic nbM neurons and 
deficits in cortical cholinergic tone [60, 82]. Several lines of evidence support the 
role of NGF in the survival of cholinergic neurons in the BF brain region. In vitro 
studies, using dissociated rat nbM cultures [83, 84] or organotypic nbM slices, [85] 
revealed that NGF treatment prevented the cholinergic neurodegeneration that was 
observed in untreated preparations. These results are similar to those demonstrat-
ing that infusion of NGF can prevent septal cholinergic neuron death following 
septo-hippocampal axotomy [86].
Finally, transgenic mice that express anti-NGF antibodies in adulthood 
display an age-dependent loss of CBF neurons [87]. These reciprocal correlations 
between reduced cortical TrkA and elevated pro-NGF levels with MMSE scores 
recommend that cholinotrophic aberrations play a significant role in cognitive 
impairment and may underlie the subsequent demise of nbM cholinergic neurons 
and extensive cholinergic deficits seen in the late stages of neurodegenerative 
disorders. Similar studies in nonhuman primates showed that recombinant 
human NGF reverses both age-related and lesion-induced cholinergic neuronal 
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degeneration and promotes cholinergic neurite sprouting [88, 89]. In addition, 
exogenous NGF rescues age-related and cholinergic lesion-induced spatial 
memory deficits in rodents [90, 91]. Thus, restoration of NGF signaling may 
demonstrate efficacious for the prevention of cognitive deficits resulting from 
nbM dysfunction.
6. TrkA ligands
Initially, the approach for the development of ligands targeting the neuro-
trophin receptors was to create small synthetic peptides with amino acid residues 
corresponding to various domains of neurotrophins and to assess those small 
molecules for their ability to mimic or inhibit the neurotrophic functions of the 
neurotrophins. The discovery of synthetic peptic ligands that correspond to specific 
neurotrophic domains with agonist and antagonist activities enacted the vital proof 
that small molecules, including those that bind monomerically to the Trk receptors 
are able to modulate the receptor functions and also provide a useful basis for the 
discovery of new non-peptide small molecules [25].
6.1 Gambogic amide
Combinatorial compound library screening identified several TrkA activa-
tors, including asterriquinone (1H5) and mono-indolyl-quinone (E5E). These 
compounds activated the receptor possibly by binding to an intercellular site that 
promoted PC12 cell survival at micromolecular concentrations [92]. Another 
screening study identified Gambogic amide (MW 628), which prevented the death 
of TrkA expressing cell line [68]. It was also found that the gambogic amide binds 
to the intracellular juxta-membrane domain of the receptor instead of the extracel-
lular ligand binding region, which suggests that gambogic amide results in allosteric 
activation of the receptor [93]. Gambogic amide was reported to activate TrkA and 
its downstream signaling pathways and promoted the survival of cells that were 
reported to express TrkA [68]. However, additional studies are required to establish 
the degree of specificity for the receptor.
6.2 Amitriptyline
The antidepressant amitriptyline was found to bind with the extracellular 
domains of the TrkA and TrkB receptors(?) and induce their activation, which pro-
moted heterodimerization that does not occur with NGF or BDNF, which suggests 
that amitriptyline induces alternative signaling outcomes [94]. Amitriptyline was 
shown to prevent the apoptosis of cultured hippocampal cells and stimulate neurite 
outgrowth in PC12 cells. In vivo studies reported that amitriptyline abridged kainic 
acid–triggered neuronal cell death. Studies in inducible TrkA-null mice demon-
strated the key role of TrkA in mediating the effects of amitriptyline. However, 
given the broad spectrum of mechanisms affected by amitriptyline, the issue of 
target specificity needs to be cautiously considered [94].
6.3 MT2
Several small peptidomimetics were also found to interact with the immu-
noglobulin-like domain of the TrkA receptor [95]. Interestingly, MT2 exhibits a 
dominant effect on the survival of PC12 cells, similar to neurotrophin NGF. It was 
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also found that the compound was less capable of inducing TrkA phosphorylation. 
Additional analysis showed that MT2 and NGF stimulated TrkA-Tyr490 phosphor-
ylation to a similar degree, where MT2 induced significantly less phosphorylation 
at Tyr674, Tyr675, and Tyr785, which insinuates that there is differential activation 
of signaling between the compound MT2 and NGF [95]. Whether this idiosyncratic 
signaling pattern provides any therapeutic compensations or disadvantages relative 
to NGF relics undetermined.
Taken together, these studies demonstrate that capable small molecules can be 
created or identified that activate TrkA receptors, in some cases through non-ligand 
receptor sites. A remaining challenge in most cases is demonstrating the degree of 
receptor specificity towards TrkA. TrkA receptor agonists and their in vitro activity 
are given below in Table 2.
6.4 Limitations of small molecule ligands
Although small molecule activators of the neurotrophin receptors have numer-
ous advantages over native neurotrophins, there are potential limitations that 
should be considered during their development.
6.4.1 Inadequate receptor specificity
• These molecules bind only to a limited number of motifs present in the protein 
interaction regions, which leads to identical epitopes occurring in another 
protein interface, which could produce off-target effects.
• Protein interfaces largely cover several interaction hotspots comprising groups 
of amino acid residues. The structures and chemical constituencies of these 
Compound Structure In-vitro activity
Gambogic amide Inhibits the death 
of hippocampal 
neurons
MT2 Inhibits the death 
of hippocampal 
neurons
Amitriptyline (binds to 
both TRKA and TRKB 
receptors)




Ligands targeting TrkA receptor.
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hotspots are not unique, but their combination in a three-dimensional struc-
ture produces a larger interaction region with the potential for high degrees of 
specificity.
6.4.2 Continuous dosing requirement
• Unlike nucleic acids and other proteins, that are permanently transduced 
with viral vectors, small molecules cannot be readily produced endogenously 
and consequently, continued exogenous administration is likely required to 
maintain their therapeutic efficacy.
6.4.3 Neurotrophin receptor mediated side effects
• Even decidedly specific small molecules may produce abnormal signaling pat-
terns through neurotrophin receptors via detouring the homeostatic mecha-
nisms (for example, proteolysis and endocytosis), which would normally limit 
the extent of receptor activation.
• These considerations, along with the potential for broad tissue exposure, 
recommend that some small molecules may have the tendency to elicit on-
target side effects like pain, epilepsy, promotion of neoplasia, or hypertension 
in neural and non-neuronal tissues.
7. Conclusion
The cholinergic system is widely affected in PD, with widespread denervation 
that contributes to a number of clinical features associated with PD, especially 
cognitive impairment, abnormal olfaction, and mood disturbances. Multisystem 
neurodegeneration may play an imperative role in the etiology of nonmotor as well 
as motor symptoms in PD. While nigrostriatal dopaminergic denervation occurs in 
all PD patients, there are PD patients with additional degeneration of non-dopami-
nergic systems (especially the cholinergic system), which significantly impacts the 
patient quality of life. NGF promotes survival and differentiation of sensory and 
sympathetic neurons and the cellular responses are elicited via binding and activa-
tion of TrkA receptors. BF cholinergic neurons are highly dependent on NGF, which 
mediates actions on the BF cholinergic neurons via NGF-specific high-affinity TrkA 
receptors. Cholinergic neurons that do not transport NGF are severely shrunken 
and downregulate the expression of TrkA receptors. Hence, restoration of NGF sig-
naling may prove efficacious for the prevention of cognitive deficits resulting from 
nbM dysfunction in PD. The development of small-molecule neurotrophin receptor 
ligands has only recently begun and only a few ligands have been created and char-
acterized. Nevertheless, observations in in vitro and in vivo studies using prototype 
compounds have indicated various vital mechanistic principles that could be used 
for the future expansion of such similar compounds. These include the discovery 
that small molecules might achieve patterns of signaling and biological end points 
that are distinct from those induced by the native neurotrophins. Additionally, 
‘monovalent’ small molecules are capable of activating TRK receptors or modulat-
ing P75NTR. These capabilities, along with the fundamental roles of neurotrophin 
receptors in several neurological disorders, will encourage the development and 
broad application of many more ligands. Moreover, several of the recently described 
compounds have favorable pharmacological features demonstrating that they could 
be advanced to clinical studies. However, the possible boundaries of small-molecule 
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modulation of neurotrophin receptors should be taken into consideration, and it 
will be crucial to better characterize in vivo target binding and establish the phar-
macodynamic properties of these compounds. Though, as neurotrophin receptor 
signaling mechanisms and pathways are better understood, it may be possible to 
design small molecules to achieve tailored signaling profiles, which could lead to the 
development of ‘disease specific designer ligands’.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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